市場調查報告書
商品編碼
1411272
局部麻醉市場規模- 按藥物類型(利多卡因、布比卡因、羅哌卡因、丙胺卡因、阿替卡因)、給藥途徑(局部、注射)、應用(牙科、急診醫學、皮膚科)、最終用途和全球預測,2024-2032年Local Anesthesia Market Size - By Drug Type (Lidocaine, Bupivacaine, Ropivacaine, Prilocaine, Articaine), Route of Administration (Topical, Injectable), Application (Dental, Emergency Medicine, Dermatology), End-use & Global Forecast, 2024-2032 |
由於各醫學專業的外科手術數量不斷增加,加上需要疼痛管理的老齡化人口不斷擴大,預計 2024 年至 2032 年局部麻醉市場規模將以 4.2% 的CAGR擴大。更高的技術進步,例如長效和微創麻醉技術的發展,正在提高患者的舒適度和滿意度。
此外,慢性疼痛和牙科手術的日益普及將加速產品的採用。最近,醫療保健專業人員越來越意識到局部麻醉在最大限度地減少全身副作用和加速患者復健方面的好處。藥物配方和遞送方法方面正在進行的研究和創新也將繼續有利於該行業的成長。例如,2021 年 12 月,Hikma Pharmaceuticals PLC 推出了鹽酸布比卡因注射液,旨在用於手術、牙科和口腔手術、診斷和治療手術以及產科手術。
局部麻醉產業依藥物類型、給藥途徑、應用、最終用途和地區進行分類。
就藥物類型而言,阿替卡因藥物領域的行業佔有率預計從 2024 年到 2032 年將以 4.3% 的CAGR成長。這種成長可歸因於阿替卡因的快速起效和延長的持續時間,以提高牙科和醫療程序的功效。此外,由於阿替卡因在疼痛管理和改善患者治療效果的有效性,人們越來越偏好阿替卡因,這將有助於增加產品需求。
預計從 2024 年到 2032 年,婦產科應用領域的局部麻醉市場佔有率將達到創紀錄的 4%CAGR。這是由於在各種婦科手術和產科干預期間擴大使用局部麻醉來進行疼痛管理。此外,越來越重視改善患者舒適度和盡量減少全身副作用將促進該細分市場的成長。
從地區來看,預計 2024 年至 2032 年歐洲局部麻醉市場的CAGR為 4.3%。這一成長可歸因於外科手術的增加、人口老齡化以及對局部麻醉益處的認知提高。醫療保健基礎設施的不斷進步,加上對以患者為中心的護理的高度重視,也將推動區域市場的成長。
Local anesthesia market size is projected to expand at 4.2% CAGR from 2024 to 2032, due to the rising number of surgical procedures across various medical specialties, coupled with the expanding aging population requiring pain management. The higher technological advancements, such as the development of long-acting and less invasive anesthesia techniques is leading to enhanced patient comfort and satisfaction.
Additionally, the increasing prevalence of chronic pain conditions and dental procedures will accelerate the product adoption. Lately, there has been growing awareness among healthcare professionals about the benefits of local anesthesia in minimizing systemic side effects and accelerating patient recovery. The ongoing research and innovation in drug formulations and delivery methods will also continue to benefit the industry growth. For instance, in December 2021, Hikma Pharmaceuticals PLC launched Bupivacaine HCl Injection, intended for use in surgeries, dental and oral procedures, diagnostic and therapeutic procedures, as well as obstetrical procedures.
The local anesthesia industry is categorized into drug type, route of administration, application, end-use, and region.
With respect to drug type, the industry share from the articaine drug segment is estimated to rise at 4.3% CAGR from 2024 to 2032. The growth can be ascribed to the rapid onset and prolonged duration of articaine for enhancing efficacy in dental and medical procedures. Moreover, the increasing preference for articaine due to its effectiveness in pain management and improved patient outcomes will contribute to the product demand.
Local anesthesia market share from the obstetrics and gynecology application segment is projected record 4% CAGR from 2024 to 2032. This is due to the increasing use of local anesthesia for pain management during various gynecological procedures and obstetric interventions. In addition, the rising emphasis on improving patient comfort and minimizing systemic side effects will boost the segment growth.
Regionally, the Europe local anesthesia market is projected to depict 4.3% CAGR from 2024 to 2032. The growth can be attributed to the rise in surgical procedures, aging population, and increased awareness of the benefits of local anesthesia. The rising advancements in healthcare infrastructure coupled with the strong focus on patient-centric care will also drive the regional market growth.